Illustrative image (Photo: VNA)
NDO/VNA – The Prime Minister has decided to use over VND 8.8 billion from the national COVID-19 vaccine fund to support the first and second phase of clinical trials of COVIVAC vaccine, which has been developed by the Health Ministry’s Institute of Vaccines and Medical Biologicals (IVAC) since May 2020.
COVIVAC uses viral vector technology on primary chicken embryo cell culture - a technique IVAC used previously to successfully produce seasonal flu vaccines. It is preserved at temperatures from 2-8 degrees Celsius.
In the first phase, it was evaluated as safe, well-tolerant and immunogenic.
The second phase will be carried out in Vu Thu district, northern Thai Binh province, with 375 volunteers.
COVIVAC is the second “made-in-Vietnam” vaccine to be allowed for clinical trials by the Health Ministry, following Nanogen company’s NanoCovax.
- Vietnam begins second phase of clinical trials for Covivac vaccine
- Vietnam produced vaccines Covivac to be evaluated in Canada
- What do we know so far about Vietnam’s homegrown COVID-19 vaccines?
- Vietnam’s second COVID-19 vaccine set to enter human trials this month
- Human trials of 2nd local COVID-19 vaccine expected in January
- Third homegrown COVID-19 vaccine to begin human trials in March
- Human trials of third homegrown COVID-19 vaccine to begin in March
- Vietnam’s 2nd homegrown COVID-19 vaccine to put into use in 2022
- Coronavirus vaccine trials in Vietnam include several phases